title: Age-related macular degeneration and the immune response: implications for therapy.
abstract: OBJECTIVE
  To review the available information concerning the immune mediation of age-related macular degeneration (AMD) and to speculate on proposed mechanisms and immunotherapy.
  
  
  METHODS
  Interpretative essay.
  
  
  METHODS
  Literature review and interpretation.
  
  
  RESULTS
  An ever-growing body of evidence is gathering concerning the role of the immune system in AMD. Evidence to date suggests that the underlying mechanism leading to AMD is the decline of the ocular downregulatory immune environment. The subsequent activation of the immune system would lead to T-cell sensitization. When combined with local antiangiogenic therapy, several existing immunotherapies may be used to downregulate the immune response, potentially leading to a more efficient inhibition of choroidal neovascularization.
  
  
  CONCLUSIONS
  The loss of the downregulatory immune environment is central to the development of AMD, permitting activation of the immune system. If so, immunotherapy could positively alter the course of the disease.
authors: Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. DrBob@nei.nih.gov
authors: Robert B
authors: RB
authors: Nussenblatt
authors: Frederick
authors: F
authors: Ferris
mesh_terms: D015551:Autoimmunity / Q000502:physiology; D006801:Humans; D007107:Immune System / Q000502:physiology*; D007167:Immunotherapy; D008268:Macular Degeneration / Q000276:immunology* / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology
references: Science. 2005 Apr 15;308(5720):385-9
references: 15761122
references: J Immunol. 2005 May 1;174(9):5187-91
references: 15843513
references: N Engl J Med. 2005 Apr 21;352(16):1685-95
references: 15843671
references: Proc Natl Acad Sci U S A. 2005 May 17;102(20):7227-32
references: 15870199
references: Hum Mol Genet. 2005 Jun 1;14(11):1449-55
references: 15829498
references: Immunology. 2005 Jul;115(3):422-30
references: 15946260
references: Arch Ophthalmol. 2005 Jul;123(7):914-21
references: 16009831
references: Immunol Rev. 2005 Aug;206:232-59
references: 16048553
references: Am J Hum Genet. 2005 Sep;77(3):389-407
references: 16080115
references: FASEB J. 2005 Oct;19(12):1683-5
references: 16099945
references: Immunity. 2005 Oct;23(4):344-6
references: 16226499
references: Arch Ophthalmol. 2005 Nov;123(11):1484-98
references: 16286610
references: Arch Ophthalmol. 2005 Nov;123(11):1570-4
references: 16286620
references: Nat Rev Immunol. 2005 Dec;5(12):953-64
references: 16322748
references: Neurobiol Aging. 2005 Dec;26 Suppl 1:94-7
references: 16198446
references: Autoimmun Rev. 2006 Mar;5(3):195-201
references: 16483919
references: Mol Vis. 2006;12:156-8
references: 16541016
references: Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1642-5
references: 16565404
references: Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1646-52
references: 16565405
references: Nat Genet. 2006 Apr;38(4):458-62
references: 16518403
references: Rejuvenation Res. 2006 Spring;9(1):111-6
references: 16608407
references: Mol Vis. 2006;12:467-77
references: 16710171
references: Science. 2006 Nov 10;314(5801):992-3
references: 17053109
references: Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3586-92
references: 12882811
references: Nat Med. 2003 Nov;9(11):1390-7
references: 14566334
references: Brain Pathol. 2003 Oct;13(4):617-29
references: 14655765
references: Development. 2004 Mar;131(5):1041-53
references: 14973287
references: Am J Ophthalmol. 2004 Mar;137(3):486-95
references: 15013873
references: Arch Ophthalmol. 2004 Apr;122(4):564-72
references: 15078675
references: J Immunol. 2004 Jun 1;172(11):6587-97
references: 15153473
references: Arch Ophthalmol. 2004 Jul;122(7):1013-8
references: 15249366
references: FASEB J. 2004 Aug;18(11):1297-9
references: 15208270
references: Invest Ophthalmol Vis Sci. 2004 Sep;45(9):3170-6
references: 15326137
references: Graefes Arch Clin Exp Ophthalmol. 1985;223(2):69-76
references: 2408968
references: Science. 1987 Aug 28;237(4818):1029-32
references: 2956685
references: Graefes Arch Clin Exp Ophthalmol. 1990;228(3):255-63
references: 2361598
references: Graefes Arch Clin Exp Ophthalmol. 1990;228(3):270-4
references: 2193850
references: J Immunol. 1990 Dec 15;145(12):4101-7
references: 2147935
references: Curr Eye Res. 1993 Feb;12(2):197-203
references: 8449029
references: Cell Immunol. 1993 Jul;149(2):315-30
references: 8330312
references: J Cell Sci Suppl. 1993;17:189-95
references: 8144697
references: Arch Ophthalmol. 1994 Jun;112(6):813-8
references: 7516148
references: Invest Ophthalmol Vis Sci. 1994 Jul;35(8):3234-50
references: 8045716
references: N Engl J Med. 1999 Jan 14;340(2):115-26
references: 9887164
references: Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3492-502
references: 11006244
references: Nat Immunol. 2001 Aug;2(8):675-80
references: 11477402
references: J Immunol. 2002 Sep 1;169(5):2736-46
references: 12193748
references: Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9256-61
references: 16754848
references: Hum Genet. 2006 Aug;120(1):139-43
references: 16710702
references: J Immunol. 2006 Aug 1;177(3):1872-8
references: 16849499
references: FASEB J. 2006 Aug;20(10):1589-98
references: 16873882
references: Invest Ophthalmol Vis Sci. 2006 Aug;47(8):3595-602
references: 16877434
references: Neurodegener Dis. 2005;2(5):267-72
references: 16909008
references: Curr Pharm Des. 2006;12(24):3101-15
references: 16918437
references: Clin Experiment Ophthalmol. 2006 Aug;34(6):590-5
references: 16925708
references: Eur J Immunol. 2006 Aug;36(8):2128-38
references: 16874737
references: Invest Ophthalmol Vis Sci. 2006 Sep;47(9):3729-35
references: 16936080
references: Invest Ophthalmol Vis Sci. 2006 Sep;47(9):3912-8
references: 16936104
references: Hum Mutat. 2006 Sep;27(9):921-5
references: 16865697
references: Exp Eye Res. 2006 Nov;83(5):1031-40
references: 16842779
references: Circulation. 2006 Oct 31;114(18):1968-76
references: 17060383
references: Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3893-7
references: 7732003
references: Addict Behav. 2007 Jan;32(1):1-8
references: 16644136
references: PLoS Med. 2006 Aug;3(8):e310
references: 16903779
references: Ann Med. 2006;38(7):450-71
references: 17101537
references: J Clin Invest. 2006 Dec;116(12):3266-76
references: 17111048
references: J Immunol. 2007 Jan 1;178(1):592-604
references: 17182600
references: J Clin Invest. 2007 Jan;117(1):89-93
references: 17200712
references: J Clin Invest. 2007 Jan;117(1):175-84
references: 17200717
references: Acta Ophthalmol Scand. 2007 Mar;85(2):230-1
references: 17305748
references: Clin Exp Allergy. 2006 Nov;36(11):1357-66
references: 17083345
references: J Cell Physiol. 2007 Jan;210(1):192-200
references: 17013806
references: Science. 2006 Nov 10;314(5801):989-92
references: 17053108
references: Am J Ophthalmol. 2002 Sep;134(3):411-31
references: 12208254
references: Invest Ophthalmol Vis Sci. 2002 Nov;43(11):3575-82
references: 12407170
references: Int Rev Immunol. 2002 Mar-Jun;21(2-3):123-52
references: 12424840
references: Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14682-7
references: 12391305
references: Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1775-82
references: 12657621
references: Eye (Lond). 2003 May;17(4):457-66
references: 12802343
references: Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7462-6
references: 10377437
references: Mol Vis. 2004 Dec 22;10:964-72
references: 15623986
references: Ann N Y Acad Sci. 2004 Dec;1029:278-85
references: 15681765
references: Am J Ophthalmol. 2005 Mar;139(3):537-40
references: 15767068
references: Annu Rev Immunol. 2005;23:901-44
references: 15771589
references: Science. 2005 Apr 15;308(5720):419-21
references: 15761120
references: Science. 2005 Apr 15;308(5720):421-4
references: 15761121